BBLGW
Bone Biologics Corp (BBLG, BBLGW
NASDAQ · Healthcare · Medical - Devices · US
$4.10
−4.65%Sep 16, 2026, 21:02 UTC
Bone Biologics Corp received a NASDAQ notice dated September 10, 2026 that it no longer complies with the minimum bid price requirement under Listing Rule 5550(a)(2), and intends to seek stockholder approval for a reverse stock split at its upcoming annual meeting.
Sep 8, 2026, 12:30 UTC
Bone Biologics Corporation announced that six hospital sites in Australia have agreed to participate in its first-in-human pilot clinical trial of NB1, its rhNELL-1-based bone graft product for spinal fusion.
Source:Aug 12, 2026, 12:00 UTC
Bone Biologics Corporation announced that the validated shelf life of its rhNELL-1 protein has been extended to 32 months, enhancing manufacturing and distribution flexibility ahead of pivotal-study scale.
Source:Jul 9, 2026, 00:00 UTC
Bone Biologics Corp signed a $3.0 million at-the-market private placement agreement with an institutional investor, issuing common stock and pre-funded warrants, plus Series F and Series G warrants, with $3.0 million in upfront gross proceeds and up to $6.0 million additional from warrant exercises.